IP Verse

Arrow Generiques competitive analysis

Loading summary...

Explore patent oppositions filed by Arrow Generiques against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3578175	Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound	AMGEN	Aug 29, 2023
EP3342411	Rapamycin Derivative For Treating Pancreas Cancer	NOVARTIS	Jun 1, 2020
EP3351246	Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis	NOVARTIS	Feb 24, 2020

Explore the latest publications and patents granted to Arrow Generiques, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Arrow Generiques, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Arrow Generiques with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ARROW GENERIQUES	2	-	-	-
NOVARTIS	6	422	-	21